BCL2L1 and hepatocellular carcinoma: In HCC models, regorafenib induces changes in BCL-2 family proteins, priming mitochondrial cell death induced by BH3-mimetics, and allowing the BCL-xL inhibitor A-1331852 to enhance regorafenib efficacy.